Syros Pharmaceuticals Inc. [SYRS] Stock Is a Great Opportunity That’s a Little Too Jacked

Syros Pharmaceuticals Inc. [SYRS] shares are up more than 67.24% this year and recently increased 0.21% or $2.05 to settle at $9.81. SYRS has a short ratio of 9.94. This implies that the market is currently less bullish on the outlook for SYRS.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


On 5, December 2020, Syros Presents New Data From Phase 2 Clinical Trial of SY-1425 and Announces Plans to Initiate Registration-Enabling Trial in MDS and Randomized Phase 2 Trial in AML. According to news published on Yahoo Finance, 61% Composite CR Rate in RARA-Positive Newly Diagnosed Unfit AML Patients, with Median Overall Survival of 18 Months Among Responders .

Analyst Birdseye View:

The most recent analyst activity for Syros Pharmaceuticals Inc. [NASDAQ:SYRS] stock was on September 22, 2020, when it was Initiated with a Buy rating from Alliance Global Partners, which also raised its 12-month price target on the stock to $18. Before that, on November 04, 2020, H.C. Wainwright Recapitulated a Buy rating and elevated its amount target to $15. On January 17, 2020, Wedbush Downgrade a Neutral rating. On March 08, 2019, JMP Securities Resumed a Mkt outperform rating and increased its price target to $18. On February 14, 2019, Oppenheimer Resumed an Outperform rating and increased its price target to $13. On November 05, 2018, ROTH Capital Upgrade a Buy rating. On March 13, 2018, Wedbush Reiterated an Outperform rating and boosted its target amount on this stock from $11 to $13. On October 31, 2017, Piper Jaffray Resumed an Overweight rating and amplified its amount target to $30.

In the past 52 weeks of trading, this stock has oscillated between a low of $4.26 and a peak of $14.69. Right now, according to Wall Street analyst the average 12-month amount target is $15.88. At the most recent market close, shares of Syros Pharmaceuticals Inc. [NASDAQ:SYRS] were valued at $9.81.


Syros Pharmaceuticals Inc. [NASDAQ:SYRS] most recently reported quarterly sales of 3.83 billion, which represented growth of 533.30%. This publicly-traded organization’s revenue is $23,880 per employee, while its income is -$908,892 per employee. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -58.77, -95.63, -84.63 and -82.70 respectively.

The Principal structure of this organization shows its whole liability to whole principal at 24.66 and the whole liability to whole assets at 17.28. It shows enduring liability to the whole principal at 23.44 and enduring liability to assets at 0.16 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 7.33 points at 1st support level, the second support level is making up to 6.89. But as of 1st resistance point, this stock is sitting at 8.22 and at 8.68 for 2nd resistance point.

Syros Pharmaceuticals Inc. [SYRS] reported its earnings at -$0.43 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.38/share signifying the difference of -0.05 and -13.20% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.38 calling estimates for -$0.4/share with the difference of 0.02 depicting the surprise of 5.00%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Syros Pharmaceuticals Inc. [NASDAQ:SYRS] is 3.50. Likewise, the Quick ratio is also the same, showing Cash ratio at 3.90. Now if looking for a valuation of this stock’s amount to sales ratio it’s 140.23 and it’s amount to book ratio is 3.78.

Insider Stories

The most recent insider trade was by Young Richard A, Director, and it was the sale of 5357.0 shares on Nov 17. Young Richard A, the Director, completed a sale of 633.0 shares on Nov 16. On Oct 19, Young Richard A, Director, completed a sale of 5673.0 shares.